AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
ImmuCell Reports Q2 2025 Financial Results: Product Sales Up 18%, Net Income $502,000
ByAinvest
Thursday, Aug 14, 2025 4:06 pm ET1min read
ImmuCell Corporation announced unaudited financial results for Q2 2025, with product sales increasing 18% to $6.4mln compared to Q2 2024. Sales for the six-month period ended June 30, 2025, rose 14% to $14.5mln, and for the twelve-month period, increased 22% to $28.3mln. The company improved its gross margin to 44% and 43% during the three-month and six-month periods, respectively, resulting in net income of approximately $502,000 and $1.9mln.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet